Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.50
+0.2%
$4.58
$3.42
$7.20
$309.18M1.941.55 million shs853,574 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.23
+4.7%
$0.97
$0.40
$2.55
$179.79M1.112.12 million shs3.08 million shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$2.81
-2.8%
$3.28
$2.41
$10.37
$217.82M2.321.08 million shs871,960 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$3.02
+2.7%
$2.81
$1.87
$11.40
$263.76M-0.161.54 million shs544,462 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+7.21%+16.77%-6.62%-19.71%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
0.00%+9.85%+191.20%+185.90%+18.62%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
0.00%+1.44%-23.43%-51.38%-66.51%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
0.00%+4.86%-0.98%-24.69%-49.07%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.739 of 5 stars
0.02.00.00.03.80.80.6
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.2179 of 5 stars
3.51.00.04.73.02.51.3
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
4.1702 of 5 stars
4.64.00.00.02.63.31.3
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4.0996 of 5 stars
3.32.00.04.13.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33139.16% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.23
Buy$14.90430.25% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.60
Moderate Buy$15.63417.38% Upside

Current Analyst Ratings Breakdown

Latest CTMX, TERN, ACB, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.00
5/16/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
4/21/2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.96$0.21 per share26.35$8.18 per share0.67
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$147.56M1.22N/AN/A($0.71) per share-3.14
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M26.92N/AN/A$6.27 per share0.45
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/A$4.13 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05110.0212.50N/A0.42%0.59%0.42%6/19/2025 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$570K$0.4813.12N/AN/A10.96%-41.47%8.11%N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$96.01M-$2.99N/AN/AN/AN/A-58.75%-47.84%8/12/2025 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.09N/AN/AN/AN/A-32.76%-31.33%8/4/2025 (Estimated)

Latest CTMX, TERN, ACB, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/19/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
5/8/2025Q1 2025
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.26+$0.03-$0.26N/AN/A
3/20/2025Q4 2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/6/2025Q4 2024
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.23$0.22+$0.45$0.22$13.53 million$38.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.04
1.04
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
7.85
7.85
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
32.99
32.99

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
7.00%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
1.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million72.78 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.52 million35.05 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4087.34 million72.11 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.50 +0.01 (+0.18%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$5.49 -0.01 (-0.18%)
As of 05/23/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.23 +0.10 (+4.69%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.22 0.00 (-0.22%)
As of 05/23/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$2.81 -0.08 (-2.77%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.82 +0.01 (+0.36%)
As of 05/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Terns Pharmaceuticals stock logo

Terns Pharmaceuticals NASDAQ:TERN

$3.02 +0.08 (+2.72%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.95 -0.07 (-2.45%)
As of 05/23/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.